This company listing is no longer active
Virbac (VIRPP) Stock Overview
Manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VIRPP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €354.25 |
| 52 Week High | €361.25 |
| 52 Week Low | €302.95 |
| Beta | 0.81 |
| 1 Month Change | -1.25% |
| 3 Month Change | n/a |
| 1 Year Change | 19.98% |
| 3 Year Change | 24.52% |
| 5 Year Change | 56.40% |
| Change since IPO | 178.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIRPP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.3% | -1.4% | 1.7% |
| 1Y | 20.0% | 40.9% | 29.5% |
Return vs Industry: VIRPP underperformed the UK Pharmaceuticals industry which returned 36.6% over the past year.
Return vs Market: VIRPP underperformed the UK Market which returned 29% over the past year.
Price Volatility
| VIRPP volatility | |
|---|---|
| VIRPP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: VIRPP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine VIRPP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 6,365 | Paul Martingell | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| VIRPP fundamental statistics | |
|---|---|
| Market cap | €2.94b |
| Earnings (TTM) | €150.89m |
| Revenue (TTM) | €1.46b |
Is VIRPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRPP income statement (TTM) | |
|---|---|
| Revenue | €1.46b |
| Cost of Revenue | €487.96m |
| Gross Profit | €976.71m |
| Other Expenses | €825.83m |
| Earnings | €150.89m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 17, 2026
| Earnings per share (EPS) | 18.01 |
| Gross Margin | 66.68% |
| Net Profit Margin | 10.30% |
| Debt/Equity Ratio | 22.3% |
How did VIRPP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/06 09:32 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virbac SA is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |